S

Sunway Medical Centre | Respiratory Medicine

Research site

(Unclaimed)

Location

5 Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya, Selangor, Malaysia

Site insights

Top conditions

Top treatments

CP-690,550

BAT

Pelabresib

Methotrexate

Lazertinib

M281

Prednisone

CPI-0610

NS-018

Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 9 total trials

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting

Advanced or Metastatic Non-small Cell Lung Cancer

Drug: Lazertinib

Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (ENERGY)

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling

Warm Autoimmune Hemolytic Anemia

Drug: M281

Drug: Placebo

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (NOVATION-1)

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling

Covid19

Biological: Placebo

Biological: Novaferon

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting

Myelofibrosis

Post-essential Thrombocythemia Myelofibrosis

Drug: Placebo

Drug: Pelabresib